Clinical Trials
16 trialsNCT02840149 2025-05-15
SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors
Jewish General Hospital
Phase 3 Completed
NCT02246127 2025-05-11
SEQTOR
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Completed
NCT04852679 2024-10-01
PALACE
Ipsen
Phase 3 Completed
NCT03136328 2023-05-09
Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan
Montefiore Medical Center
Phase 3 Completed
NCT02588170 2023-03-30
Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors
Hutchmed
Phase 3 Completed
NCT02589821 2023-03-30
Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors
Hutchmed
Phase 3 Completed
NCT03673943 2022-12-22
Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE
Radiomedix, Inc.
Phase 3 Completed
NCT01842165 2022-11-10
LUMEN
Jules Bordet Institute
Phase 3 Completed
NCT00774930 2022-10-14
ELECT
Ipsen
Phase 3 Completed
NCT00842348 2022-10-12
NET729
Ipsen
Phase 3 Completed
NCT01578239 2022-04-04
NETTER-1
Advanced Accelerator Applications
Phase 3 Completed
NCT03042416 2022-01-10
18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety
University of Alberta
Phase 3 Completed
NCT01524783 2021-08-05
RADIANT-4
Novartis
Phase 3 Completed
NCT00171873 2020-03-26
Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
Philipps University Marburg
Phase 3 Completed
NCT00037869 2018-10-31
High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00510068 2015-07-01
RADIANT-3
Novartis
Phase 3 Completed